470 patents currently held
124 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3 more records may belong here and await a decision; they are not counted.
The next term ends in Jan 2027. from the record
Of the 124 now held by other companies, 10 name Noster Inc. as their current owner, and 114 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
46
Ending by 2030
Jan 2027
Next term end
418
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jun 2027 · High confidence
Also notable
Ends Sep 2029 · High confidence
Also notable
Ends Sep 2030 · High confidence
Induced Pluripotent Stem Cells Produced with OCT3/4, KLF4 and SOX2
US 8,278,104
The most cited patent in this portfolio, cited by 155 later US patents, top 5% of utility patents granted in 2012 in our data. Protection runs to 2027. A terminal disclaimer caps this term to an earlier patent's.
Induced Pluripotent Stem Cells Produced Using Reprogramming Factors and a Rho Kinase Inhibitor or a Histone Deacetylase Inhibitor
US 8,211,697
Cited by 105 later US patents, top 10% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Compositions and Methods for the Treatment of Metabolic Disorders
US 8,207,196
Cited by 27 later US patents, top 25% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Nov 19 to 30, 2026 · next Nov 19
- 13 fees due Dec 2 to 27, 2026 · next Dec 2
- 12 fees due Jan 2 to 30, 2027 · next Jan 2
- 8 fees due Feb 4 to 22, 2027 · next Feb 4
- 4 fees due Mar 1 to 17, 2027 · next Mar 1
- 8 fees due Apr 6 to 29, 2027 · next Apr 6
- 9 fees due May 3 to 26, 2027 · next May 3
- 7 fees due Jun 5 to 30, 2027 · next Jun 5
- 10 fees due Jul 2 to 26, 2027 · next Jul 2
- 9 fees due Aug 9 to 27, 2027 · next Aug 9
- 11 fees due Sep 1 to 30, 2027 · next Sep 1
- 9 fees due Oct 7 to 23, 2027 · next Oct 7
- 5 fees due Nov 5 to 12, 2027 · next Nov 5
Recent changes
- Oct 28Assignment recorded on 1 record: Tomonaga, Keizo and 1 other to Kyoto University Recorded Oct 28, 2026, executed Jul 14, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76538, frame 275.
- Oct 18Assignment recorded on 1 record: Honjo, Tasuku and 2 others to Kyoto University Recorded Oct 18, 2026, executed Jul 10, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76416, frame 749.
- 23 of the patents on this record were granted since Aug 20, 2026
- 9 terms have ended since Aug 20, 2026
What they patent
The 5 largest of its 418 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| METHOD FOR DETERMINING DESIRED CELL TYPE USING EXPRESSION OF miRNA AS INDICATOR | 9 in force | to Sep 2038 |
| Compositions and Methods for the Treatment of Metabolic Disorders | 6 in force | to Sep 2030 |
| Method of Screening ATP11C or CDC50A Inhibitor | 3 in force | to Jun 2035 |
| Induced Pluripotent Stem Cells Produced Using Reprogramming Factors and a Rho Kinase Inhibitor or a Histone Deacetylase Inhibitor | 3 in force | to Sep 2029 |
| Induced Pluripotent Stem Cells Produced with OCT3/4, KLF4 and SOX2 | 3 in force | to Jun 2027 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,957,620 | Two-Dimensional Photonic Crystal Resonator held by Kyoto University and Sumitomo Electric Industries, Ltd. In force · High confidence | In force | High confidence | |
| US 12,012,615 | Improved Method of Making Induced Pluripotent Stem Cells Using P53 Inhibitors In force · Medium confidence | In force | Medium confidence | |
| US 8,048,999 | Nuclear Reprogramming Factor In force · High confidence | In force | High confidence | |
| US 8,278,104 | Induced Pluripotent Stem Cells Produced with OCT3/4, KLF4 and SOX2 In force · High confidence | In force | High confidence | |
| US 9,213,999 | Providing iPSCs to a Customer In force · High confidence | In force | High confidence | |
| US 12,466,863 | Nuclear Reprogramming Factor and Induced Pluripotent Stem Cells In force · High confidence | In force | High confidence | |
| US 7,936,801 | Two-Dimensional Photonic Crystal Surface Emitting Laser Light Source held by Kyoto University and Rohm Co., Ltd. In force · High confidence | In force | High confidence | |
| US 8,923,358 | Two-Dimensional Photonic Crystal Surface Emitting Laser Light Source held by Kyoto University and Rohm Co., Ltd. In force · High confidence | In force | High confidence | |
| US 8,379,686 | Two-Dimensional Photonic Crystal Surface-Emitting Laser Light Source held by Kyoto University and Rohm Co., Ltd. In force · High confidence | In force | High confidence | |
| US 8,927,578 | Compositions and Methods for the Treatment of Metabolic Disorders In force · High confidence | In force | High confidence |
Also on record, not counted in the 470: 124 patents in force now held by others · 320 patents ended · 384 applications pending · 428 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.